---
layout: post
title: "Prospective Grant of an Exclusive Patent License: N-butyldeoxynojirimycin To Treat Smith-Lemli Opitz Syndrome (SLOS) and Diseases That Exhibit a Similar NPC-Like Cellular Phenotype"
date: 2026-02-05 19:09:10 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-07316
original_published: 2021-04-09 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: N-butyldeoxynojirimycin To Treat Smith-Lemli Opitz Syndrome (SLOS) and Diseases That Exhibit a Similar NPC-Like Cellular Phenotype

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** April 09, 2021 00:00 UTC
**Document Number:** 2021-07316

## Summary

The National Institute of Child Health and Human Development, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. and foreign Patents and Patent Applications listed in the Supplementary Information section of this notice to SubRed Pty Ltd located in Australia, registered in Victoria.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/04/09/2021-07316/prospective-grant-of-an-exclusive-patent-license-n-butyldeoxynojirimycin-to-treat-smith-lemli-opitz)
- API: https://www.federalregister.gov/api/v1/documents/2021-07316

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
